PI3K/mTOR双重抑制剂LY3023414联合卡铂对子宫内膜癌的协同作用
该研究探讨PI3K/mTOR双重抑制剂LY3023414与卡铂联合抑制子宫内膜癌的协同效应及机制。体外实验显示联合治疗协同抑制EC细胞增殖、集落形成并促进凋亡,激活ATM/Chk2通路;体内HEC-1A皮下移植瘤(携带PIK3CA突变)及不同PI3K通路突变模式的PDX模型中联合治疗表现出协同抗肿瘤效果,且未增加裸鼠药物毒性。
要点
- LY3023414联合卡铂在EC细胞及部分PDX模型中协同抗肿瘤,不增加毒性
- 协同机制可能与增强卡铂诱导的DNA损伤反应和细胞凋亡有关
- 抗肿瘤效果可能与PI3K通路突变模式相关,为个体化治疗提供实验依据
核心结论
- PI3K/mTOR双重抑制剂LY3023414与卡铂联合在EC细胞系和部分PDX模型中具有协同抗肿瘤作用,且不增加单药毒性。
研究设计与样本
- 体外研究联合治疗对细胞活力、长期存活和细胞凋亡的影响。
- 体内采用HEC-1A细胞皮下移植瘤模型及不同PI3K通路突变模式的PDX模型。
- 探索ATM/Chk2和PI3K信号通路机制并观察联合治疗毒性。
主要发现
- 联合治疗协同抑制EC细胞增殖和集落形成,促进凋亡,显著激活ATM/Chk2信号通路。
- 在携带PIK3CA突变的HEC-1A皮下移植瘤中LY3023414与卡铂具有协同抗肿瘤作用。
- 不同PI3K通路突变模式的EC PDX对联合治疗敏感性不同,协同抗肿瘤效果存在差异。
- 联合治疗组裸鼠未见药物毒性增加。
临床怎么用
- 联合方案可能为EC个体化治疗提供实验依据,抗肿瘤效果或与PI3K通路突变模式相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Our study aims to investigate whether PI3K/mTOR dual inhibitor LY3023414 has synergistic effects with carboplatin in suppressing endometrial cancer (EC), and explore the mechanisms and toxicity of combined therapy. METHODS: The effects of combined therapy of LY3023414 and carboplatin on cell viability, long-term survival and cell apoptosis were studied in vitro, and on subcutaneous xenograft model of HEC-1A cells and patient derived xenograft (PDX) models with different PI3K pathway mutational patterns in vivo. The synergistic mechanisms were explored on ATM/Chk2 and PI3K signaling pathway. The toxicity of combined therapy was also observed. RESULTS: Combined treatment of LY3023414 and carboplatin synergistically inhibited proliferation, colony formation, promoted apoptosis of EC cells, and significantly activated ATM/Chk2 signaling pathway. LY3023414 had synergistic anti-tumor effects with carboplatin in HEC-1A subcutaneous xenograft which harbors PIK3CA mutation. The sensitivity to LY3023414 and carboplatin differed in PDX of EC cases with different mutational patterns of PI3K pathway, and combined therapy exhibited distinct synergistic anti-tumor effects in those harboring different PI3K pathway mutations. No increased drug toxicity in nude mice was seen in combined groups. CONCLUSIONS: Combined therapy of PI3K/mTOR dual inhibitor LY3023414 and carboplatin had synergistic anti-tumor effects in EC cell line and some of the PDX EC models, without increasing the toxicity of single drug. Enhanced carboplatin-induced DNA damage response (DDR) and cell apoptosis may be the mechanisms of synergistic effects. The anti-tumor effects may correlate with the mutational pattern of PI3K pathway, which provides experimental basis of individual treatments of ECs in the future.
引用
- Jia N, Che X, Jiang Y, et al. Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma. Gynecol Oncol. 2021. PMID: 34183163. doi:10.1016/j.ygyno.2021.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。